San Diego, CA. January 7, 2019 – Medical Affairs 360 LLC, a medical advisory firm offering services to pharmaceutical and biotechnology companies, is pleased to congratulate its client partner, Loxo Oncology, Inc., on its acquisition by Eli Lilly and Company in a transaction valued at approximately $8.0 billion.
“We wish to congratulate Loxo Oncology and Eli Lilly for this landmark agreement.” said Kenneth Tong, President and Founder of Medical Affairs 360 LLC.
Medical Affairs 360 provided clinical advisory and pharmacovigilance support at the onset of early phase I research through FDA approval including product launch activities for Vitrakvi®, a first-in-class oral TRK inhibitor for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation.